Figure. 2.

Gemcitabine pre-treatment of PDAC cells increases nab-paclitaxel uptake in vitro A. AsPC-1 and B. HPAF-II cells +/− pre-treatment with gemcitabine (50 nM) for 24 hours were pulsed with NP on day 2 (Gem(D1)NP(D2)) or day 3 (Gem(D1)NP(D3)) for one hour followed by immunofluorescence analysis of human albumin. Representative set of images of NP alone or cells pre-treated with gemcitabine for 24 hours are shown. C-D. Fluorescence intensity quantification was performed on Image J software based on raw integrated density of individual cells. E-F. Intracellular concentration of paclitaxel measured by mass spectrometry was determined in ASPC-1 and HPAF-II cells after treatment with vehicle (control), paclitaxel (100 nM), or NP (100 nM) for one hour. In the last 3 conditions, gemcitabine (50 nM) was delivered concurrent [Gem(D1)NP(D1)], 24 hours [Gem(D1)NP(D2)] or 48 [Gem(D1)NP(D3)] hours prior to NP as indicated. ****p<0.0001.